Teva has appointed Dr Michael Hayden as its new president of global R&D and chief scientific officer at the firm’s …
MHRA approves Romvimza for tenosynovial giant cell tumour
Panthera opens clinical trial site at Keele University
Santen joins inaugural Global Summit for Eye Health as partner

